GALE 302

Drug Profile

GALE 302

Alternative Names: E39'; Folate binding protein J65 - Galena Biopharma; J65

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Galena Biopharma
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides; Stem cell therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Ovarian cancer

Most Recent Events

  • 09 Mar 2017 COL George Peoples and M.D. Anderson Cancer Center completes a phase Ib/II trial in Breast cancer and Ovarian cancer (Prevention of relapse) in USA before March 2017 (NCT02019524)
  • 14 Nov 2016 Analysis of post-booster immunogenicity data from a phase Ib trial in Ovarian cancer and Breast cancer released by Galena Biopharma
  • 20 Oct 2016 Immunogenicity data from a phase Ib trial in Breast cancer and Ovarian cancer released by Galena Biopharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top